# GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

> **NCT06162715** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Vanderbilt University Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Severe Obesity
- Obesity
- BMI Greater Than 30

## Interventions

- **DRUG:** Tirzepatide
- **OTHER:** Standard of Care post-gastric bypass

## Key facts

- **NCT ID:** NCT06162715
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-10-30
- **Primary completion:** 2027-05
- **Final completion:** 2027-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06162715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06162715, "GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06162715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*